Status:
RECRUITING
Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature
Lead Sponsor:
Dong-A ST Co., Ltd.
Conditions:
Growth Hormone Deficiency
Idiopathic Short Stature
Eligibility:
All Genders
2+ years
Brief Summary
This study evaluates long-term safety and effectiveness of Growtropin®-II treatment in children with short stature.
Eligibility Criteria
Inclusion
- Children with short stature by growth hormone deficiency(GHD) or idiopathic short stature (ISS) or turner's syndrome(TS) or small for gestational age(SGA)
- Children who has official height record at least 6 months prior
Exclusion
- Children with Epiphyseal closure
Key Trial Info
Start Date :
February 8 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2031
Estimated Enrollment :
2500 Patients enrolled
Trial Details
Trial ID
NCT04798690
Start Date
February 8 2021
End Date
December 1 2031
Last Update
April 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yonsei University Health System, Severance Hospital
Seoul, Seodaemun-gu, South Korea, 03722